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The present study. O’Donoghue et al. (I) present data in 
this izsoe of the Journal suggesting that early aotomatic 
defibrillator implantation, as compared with implantation 
after prolonged hospita!ization for setial electrophysiologic 
testing, may be cast.effective in patients with recurrent 
ventricular tachycardia and cardiac arrest. Cost-saving 
changes ia health care delivery will have a lasting impact 
only if they also represent good medical practice. If a change 
represents both good economics and good medicine, then 
everyone (patients, physicians, hospitals and third party 
payers) is supportive and it can he implemented with little 
controversy. Outpatient coronary angiography is an example 
of a change in practice patterns that has proved to be safe. 
eBicient, cost-effective and liked by patients who dc not 
need to spendanightinastrange hospital Led. In oorcorrent 
eowromnent of irrational and inadequate Medicare reim- 
bursement for electrophysiologic procedures. practices that 
constitute good economics for third party payers who reim- 
bdrre hospitats fw srrvices rendered may not save money in 
the world of Medicare economics. Wrc.2 parsing judgme,lt 
on the proposal of O’Donoghue et ai. (I), we most examine 
whether it makes both good medical sense and goad eco- 
noouc sense. it is also iriteresting to altempt to estimate its 
impact on Medicare reimburserrents. 
centers a high propardon of patients .who undergo serial 
electrophysiologic testing eventually receive a defibrillator 
because no dfing can be found to prevcl;: arrhythmia induc- 
tion. Discussions with colleagues from around the uwld 
indicate that the proporticn of dmg responders seems to 
have declined substantially since the early days afserizl drug 
testinc. The findine in the oresent stodv (1) that 37% _I 
patie& respond to&tiorrhyihotic therap; is probably at the 
high end of the spictrom. This is partly because of the 
authors’ exclusion of any patients who had received prior 
antiwrhythmic therapy or required concomitant bypass sor- 
gery or aneurysm resection, all factors that reduce the 
chances of finding an effective drug at electrophysiologc 
testing (2). At many centers, when such patients are not 
excluded, the drug sttcccss rote is probably one half that of 
the present study. Even in patients whose tochyorrhythmia 
becomes noninducible during serial electraphysiologic drug 
testing, the I year sodden death rote of approximalely 6% to 
8% (3) is considerably hither than the 1% to % annual 
sodden death rate rep&ted for patients undergoing defibril- 
lator implantation (4). Doting the 1st year, however, the 
tower sudden death rate in the latter moor) may be offset in 
part by the I% to 2% operative mart&y &e, the 1% to 2% 
rate of {nfection and the 1% to 2% rote of oatients who have 
an unacceptably high defibrillation threshaId that makes the 
device fitnctionally useless. One would anticipate a lower 
long-term monality rate after the 1st year for patients 
undergoi-.g early automatic implantable cardiovener- 
defibrillator ins&on because the I% annual sudden death 
n!e ir, patients who receive a defibrillator extends to 25 
yearsaffollow “p(4). Similarlong-term datado not exist for 
patients whose ventricular tachyarrhythmia bemow ttonin- 
ducible at electrophysiok& study. One would anticipate 
that by 4 to 5 years of follow-up progression of underlying 
disease and changing myocardial substrate would result in ao 
increasing number of late antiarrhythmic drug failures in the 
patients whore arrhythmia became electrophysiologkally 
noninducible and who were treated with drugs alone. 
Advzmtws of serial ele&ophysi&ie Icstiaa. There may 
be many hidden advantages tia mode&e!y lengthy hospital 
SW before defibrillator imolaotation. These include the 
opportunity to develop npp&t between the patient and the 
physician and nursing sta6 caring for the patient. t3ecause 
implanted antitachycardia devices are complex, bulky, phys- 
ically unattractive to the patient and may &liver unpleasant 
shocks, a period of several days of patient education is 
recommended. Such educatton is often undertaken during 
the period of serial electroohysiolonic tertina with the antic- 
ipation that the drug trialswi~l pro&bly be o&uccessfol and 
the wtient will require 80 implanted device. The drugtesting 
period also permits observation of the patient’s underlying 
rhythm to detect episodes of nonsustained supravemricular 
orvenbiculartacbycardias that might inappropn’ately trigger 
a device. Such findings permit the initiation of antianhyth- 
mic therapy that will result in fewer snbsequent defibrillator 
discharges and fewer rebospitdilabons to adjust medica- 
tions. Finally. we frequently utilize information gained from 
unsuccessful drug trials during serial ekctrophysiologic drug 
testing. After defibrillator implantation. many patients are 
treated with drugs that proved partihily eifective during 
earlier ekctrophysiologic testing. These nrugs may I) make 
ventricular tachycardia more difficult to induce, thereby 
minimizing the number of shocks received; 2) slow down the 
ventricular tachycardia to prevent presyncope or syncope 
before a shock is delivered; or 3) make the tachycardia more 
amenable to antitachycardia pacing. an observation that will 
become increasingty important as devices attain antitachy- 
cardia pacing capabilities. 
cluded all parienrs een with sustained ventricular iacbvcar- 
dia or cardiac arrest (including those who had rec&ed 
earlier drug therapy or who needed bypass surgery or 
aneurysm resection). the economic advantye to early de- 
fi%llalor implanation would probabiy have been even 
greater than that reported. Inclusion of those patients mitit 
show tba: >8J3% of all patients have unsuccessful serial dig 
testing and undergo latedefihrillator implantation. With such 
a high percentage of patients ultimately getting an implanted 
device, the cost savings from early implantation would 
appear to be substantid. 
Is euIy ImpImttetien of lhe ~utontalie implentable eerdi+ 
verkr&tibriUatw acaptabk to the pal&t? Before taly 
implantation of implantable delibrillators becomes a aide- 
spread practice, it must be made acceptable to patients. 
Given a choice between a medical ar,d surgical treatment. 
patients overwhelmingly choose medical t&atment unless 
the surgical therapy is clearly superiar in terms of life-style 
or survival. Most life-style advantages eem to fall strongly 
on the side of taking an antimrhythmic dreg shown to be 
effective at serial electraphysiologic study, provided the 
drug did not cause too many side eects. Although some 
patients would willingly accept a device to gain freedom 
from drug therapy two thirds of our patients with an im- 
planted defibrillator now receive concomitant reatment with 
antiarrhythmic drugs (41. In addition. there patienls fre- 
quently take medications for heart failure and other chronic 
illnesses. Therefore, eliminating d few pills a day will not 
make a major impact on the polypharmacy they must en- 
dure. To convince patients that early defibrillator implanta- 
tion is appropriate, it will be necessary to show a clear 
long-term survival benefit or to demonstrate that drugs alone 
are unlikely to be effective. Recommendation of an opera- 
tion solely because it is cheaper will probably never be 
acceptable to patients. Although patients. physicians and 
hospitals become accustomed to the denial of payment for 
medical services by third party payers, it would clearly be 
precedent setting for third party payers to demand that a 
patient have a defibrillator implanted on the basis of eco- 
nomics alone. 
computer model to assess the tree economic impact of early 
defibrillator imdantation. A number of factors could hake a 
negative impact on tbe apparent cost savings. If more 
padems decided to undergo coronary bypass surgery be- 
cause they were also going to undergo defibrillator implan- 
tation. the cost would be driven upward. Cutting short the 
hospital stay before defibriliator implantation may result in a 
longer postoperative hospital stay to manage episodes of 
nonsustained ventricular tachvcardia. frequent bouts of EUE- 
rained ventricular tachycmdia or paroxysmal rupmventric- 
ular tachycardias, all of which are cum:ntly discovered and 
dealt with before device implantation. An occasional de- 
fibrillator system infection would alsoo5set some ofthe cost 
savings. The present study provides few data to permit one 
to estimate the long-rerl cost of the therapy given with 
drugs proved effective at electraphysiologic study versus 
early defibrillator implantation. The frequency of dmg ad- 
ministration in the de6brillator group and the rate and causes 
of rehospitalization oust be known to calculate long-term 
costs in each group. The cost of future generator changes for 
patients receiving early detibrillators must also be factored 
into the cost. 
Does II Make Economic Sense? 
Ahbouglt O’Donoghue et al. (I) did not find a statistically 
sign&ant diierence between the cost of early defibrillator 
implantation versus implantation after failure of serial drug 
testing, their data definitely suggest that early implantation 
may have an economic advantage. If the authors had in- 
Factors inRwncing the eaxmk im 1. It will probably 
reqmre a prospective study or a sophisticated long-term 
Impact on Medicare Reimbursements 
Impact en hospitals. If early implantation of detibrillators 
did prove cost elfective, it would be readily endorsed by 
those third party payers whose reimbursement to rhe hospi- 
tal vaguely resembles the hospital’s cost ofdelivering health 
are. Medicare diagnosis-related group reimbursements 
wre established to reimburse hospitals for the average cost 
of treating a disease based on a given diagnosis. It is 
assumed that the hospital will make money on some patients 
with a given diagnosis and lose money on others. Unfortu- 
nately. hospitals lose money on every single patient who 
undergoes electrophysiologic studies for recurrent ventricu- 
lar tachycardia and cardiac arrest. The economic impact of 
these losses is focused on a small number of tertiary referral 
centers that treat large numbers of such patients. From the 
hospital’s viewpoint, decisions for early implantation must 
not be based on the usual economic considerations but 
rather on “minimzing the losses.” If a hospital loses sub- patients only after two or perhaps three antnrrhythmic drug 
stantially more money for each patient in whom a defibri- trials (which can be undertaken within 5 to 7 days) have 
lator is imolanted than for each oatient in whom a drw. is proved unsuccessful. Additional drw trials rarely result in 
successful. the net economic impact to the hospital maynot hrus successes. 
favor early im&+nlation in Medicare patients. It is imparsi- Early drfihrilloror implnnrorian sho,dd be &red IO: 
ble to speculate on actual economic impact to hospitals. for 
such an analysis requires an understanding of diagnosis- 
related groups. modifiers, autliers, and the use of computer 
programs that are difficult for most cardiologists to compre- 
hend. Because current Medicare guidelines require that 
patients have had unsuccessful drug therapy before delibril- 
later implantation. hospitals would nsk losing all reimburse- 
ment on Medicare patients if they attempted to implement a 
program of early device implantation. 
Impact on Mrdiiare and third party payers. Under the 
current diagnosis-related group reimbursement system, it 
costs Medicare substantially less to treat a patient for 
ventricular tachycardiaicardiac arrest if no defibrillator is 
I, Any patient requiring concomitant cardiac surgery. 
2. Patients who have poor left ventricular function or left 
ventricular aneurysm or who have failed previous 
empiric antiarrhythmic drug trials. The likelihood of 
drug success in those patients seems low. 
3. Any patient who desires the additional protection 
awinst sudden death afforded by the implantable de- 
fibrillator. 
Law defibrillator implantarion should be undennken uf 
ler three or more serial elecrrophysiologic studies only in: 
I. Patients who, after education about implanted defibril- 
Iators. slrongly desire to pursoe a ioxe of nedical 
therapy. 
implanted. For those patients who do receive a device, 2. Patients with a relative contraindication to the surgical 
Medicare pays the same to the hospital whether the electm- procedure required for device implantation. 
physiologist does I or IO electrophysiologic studies before Finoily, Medicare rnu~t recognize Ihe inequiria in irs 
defibrillator implantation. Thus, it costs Medicare more current sysrem of reimbursement 10 hospitals for poiienls 
money if more defibrillators are implanted regardless of wirk life-e-rhrtwening arrhythmias whc undergo electrophys- 
when during the hospitalization they are implanted. If63% of iologic evaluation and defibrillator implantation. Although 
@enIs receive such a device, it costs Medicare less than if Medicare has recently tried to improve the situation. the 
100% of patients receive a device. Unless strong medical changes fall far shon of permitting even the most efficient of 
arguments can be made justifying early implantation, there hospitals to recover the cost of caring for these patients. 
seems to be little incentive for Medicare to change its correct Medicare may need to establish centers of both excellence 
implantation gGdelines. Many state agencies and third pny and efficiency for the implantation of these devices and work 
payers follow Medicare’s indications for and reimbursement out a cotttractttal agreement that adequately reimburses 
for various medical procedures. In the case of defibrillator hospitals for their average costs. 
implantation, third parry payers may need to take the lead in 
encouraging early implantation of devices if they wish to 
fully realize any possible economic benefits. References 
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